Cargando…

1-Kestose supplementation mitigates the progressive deterioration of glucose metabolism in type 2 diabetes OLETF rats

The fructooligosaccharide 1-kestose cannot be hydrolyzed by gastrointestinal enzymes, and is instead fermented by the gut microbiota. Previous studies suggest that 1-kestose promotes increases in butyrate concentrations in vitro and in the ceca of rats. Low levels of butyrate-producing microbiota ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Ayako, Kadota, Yoshihiro, Kamio, Rina, Tochio, Takumi, Endo, Akihito, Shimomura, Yoshiharu, Kitaura, Yasuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515885/
https://www.ncbi.nlm.nih.gov/pubmed/32973311
http://dx.doi.org/10.1038/s41598-020-72773-2
_version_ 1783586894756446208
author Watanabe, Ayako
Kadota, Yoshihiro
Kamio, Rina
Tochio, Takumi
Endo, Akihito
Shimomura, Yoshiharu
Kitaura, Yasuyuki
author_facet Watanabe, Ayako
Kadota, Yoshihiro
Kamio, Rina
Tochio, Takumi
Endo, Akihito
Shimomura, Yoshiharu
Kitaura, Yasuyuki
author_sort Watanabe, Ayako
collection PubMed
description The fructooligosaccharide 1-kestose cannot be hydrolyzed by gastrointestinal enzymes, and is instead fermented by the gut microbiota. Previous studies suggest that 1-kestose promotes increases in butyrate concentrations in vitro and in the ceca of rats. Low levels of butyrate-producing microbiota are frequently observed in the gut of patients and experimental animals with type 2 diabetes (T2D). However, little is known about the role of 1-kestose in increasing the butyrate-producing microbiota and improving the metabolic conditions in type 2 diabetic animals. Here, we demonstrate that supplementation with 1-kestose suppressed the development of diabetes in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, possibly through improved glucose tolerance. We showed that the cecal contents of rats fed 1-kestose were high in butyrate and harbored a higher proportion of the butyrate-producing genus Anaerostipes compared to rats fed a control diet. These findings illustrate how 1-kestose modifications to the gut microbiota impact glucose metabolism of T2D, and provide a potential preventative strategy to control glucose metabolism associated with dysregulated insulin secretion.
format Online
Article
Text
id pubmed-7515885
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-75158852020-09-29 1-Kestose supplementation mitigates the progressive deterioration of glucose metabolism in type 2 diabetes OLETF rats Watanabe, Ayako Kadota, Yoshihiro Kamio, Rina Tochio, Takumi Endo, Akihito Shimomura, Yoshiharu Kitaura, Yasuyuki Sci Rep Article The fructooligosaccharide 1-kestose cannot be hydrolyzed by gastrointestinal enzymes, and is instead fermented by the gut microbiota. Previous studies suggest that 1-kestose promotes increases in butyrate concentrations in vitro and in the ceca of rats. Low levels of butyrate-producing microbiota are frequently observed in the gut of patients and experimental animals with type 2 diabetes (T2D). However, little is known about the role of 1-kestose in increasing the butyrate-producing microbiota and improving the metabolic conditions in type 2 diabetic animals. Here, we demonstrate that supplementation with 1-kestose suppressed the development of diabetes in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, possibly through improved glucose tolerance. We showed that the cecal contents of rats fed 1-kestose were high in butyrate and harbored a higher proportion of the butyrate-producing genus Anaerostipes compared to rats fed a control diet. These findings illustrate how 1-kestose modifications to the gut microbiota impact glucose metabolism of T2D, and provide a potential preventative strategy to control glucose metabolism associated with dysregulated insulin secretion. Nature Publishing Group UK 2020-09-24 /pmc/articles/PMC7515885/ /pubmed/32973311 http://dx.doi.org/10.1038/s41598-020-72773-2 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Watanabe, Ayako
Kadota, Yoshihiro
Kamio, Rina
Tochio, Takumi
Endo, Akihito
Shimomura, Yoshiharu
Kitaura, Yasuyuki
1-Kestose supplementation mitigates the progressive deterioration of glucose metabolism in type 2 diabetes OLETF rats
title 1-Kestose supplementation mitigates the progressive deterioration of glucose metabolism in type 2 diabetes OLETF rats
title_full 1-Kestose supplementation mitigates the progressive deterioration of glucose metabolism in type 2 diabetes OLETF rats
title_fullStr 1-Kestose supplementation mitigates the progressive deterioration of glucose metabolism in type 2 diabetes OLETF rats
title_full_unstemmed 1-Kestose supplementation mitigates the progressive deterioration of glucose metabolism in type 2 diabetes OLETF rats
title_short 1-Kestose supplementation mitigates the progressive deterioration of glucose metabolism in type 2 diabetes OLETF rats
title_sort 1-kestose supplementation mitigates the progressive deterioration of glucose metabolism in type 2 diabetes oletf rats
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515885/
https://www.ncbi.nlm.nih.gov/pubmed/32973311
http://dx.doi.org/10.1038/s41598-020-72773-2
work_keys_str_mv AT watanabeayako 1kestosesupplementationmitigatestheprogressivedeteriorationofglucosemetabolismintype2diabetesoletfrats
AT kadotayoshihiro 1kestosesupplementationmitigatestheprogressivedeteriorationofglucosemetabolismintype2diabetesoletfrats
AT kamiorina 1kestosesupplementationmitigatestheprogressivedeteriorationofglucosemetabolismintype2diabetesoletfrats
AT tochiotakumi 1kestosesupplementationmitigatestheprogressivedeteriorationofglucosemetabolismintype2diabetesoletfrats
AT endoakihito 1kestosesupplementationmitigatestheprogressivedeteriorationofglucosemetabolismintype2diabetesoletfrats
AT shimomurayoshiharu 1kestosesupplementationmitigatestheprogressivedeteriorationofglucosemetabolismintype2diabetesoletfrats
AT kitaurayasuyuki 1kestosesupplementationmitigatestheprogressivedeteriorationofglucosemetabolismintype2diabetesoletfrats